Company

Our ethos is to support regional networks of Primary and Secondary care physicians who have a genuine interest in clinical research. Central to this is patient safety and well-being throughout the whole trial process.

Concept.

We provide the link that brings together physicians and their patient populations in order to facilitate the efficient running of clinical trials.

We manage the whole trial process and every aspect of the relationship between Investigator and Sponsor to ensure the trial targets and timelines are achieved.

Overcoming current resource obstacles

Traditionally, physicians, acting independently, have contracted with pharmaceutical companies and CROs to act as trial sites. To deliver on patient recruitment and site management duties they had to juggle existing clinical staff who were often overstretched. The outcome was slow recruitment and poor data quality.

More recently, the UK has seen an overall reduction in the number and size of trials. This has meant physicians are finding it difficult, if not impossible, to employ clinical staff to run trials. As a result, the number of investigators able to conduct trials has fallen sharply and the trend is set to continue.

By offering flexible support to physicians, we provide the infrastructure support needed to overcome these obstacles. With continued growth our goal is to further raise the profile of UK research.

top


Organisation

Our established team of experienced clinical research professionals is well placed to manage your trial, giving it the level of attention it demands to ensure timelines, quality and cost targets are strictly adhered to throughout the whole trial process.

Our company structure, made up of Clinical Operations, Study Management, Business Development and our Scientific Advisory Group, ensures the highest standards in scientific integrity, study management and on-going customer satisfaction

top


Key Staff

Tom Shelly MBA, FCA Managing Director
Prior to the start-up of Cambridge Clinical Research, Tom was Vice President/CFO of Tecan US, North Carolina from 1989-2000. Tecan is a world leading supplier of automation and liquid handling solutions for drug discovery to the pharmaceutical industry, clinical reference laboratories and blood banks. From 1985-1989 he was financial controller of Odenberg US, a food technology company in Sacramento CA. He is a fellow of the Institute of Chartered Accountants of Ireland. He received his MBA from the Kenan Flagler Business School at the University of North Carolina at Chapel Hill and his Bachelor of Commerce degree from University College Dublin, Ireland.

Karen Norcott RN BSc (Hons) Clinical Operations Manager
Karen joined CCR in 2000 as a Clinical Research Nurse (CRN). Over the last 5 years she has successfully run trials across many therapeutic areas. In 2002, Karen was promoted to Senior CRN where her responsibilities included managing the work of 4 CRNs across 4 hospital sites. In early 2006 Karen was promoted to Clinical Operations Manager. Prior to CCR, Karen held nursing positions within the NHS and private sectors. She has over 10 years experience within the pharmaceutical industry

top


Staff Recruitment

Our Current Vacancies

There are no vacancies at present.

Future Vacancies

We are always on the look-out for talented Research Nurses. If you are a qualified nurse located in East Anglia or Yorkshire, please contact us directly. You may like to refer to our Skills Check list to judge your suitability for the position - this is entirely informal and is not used in any application or interview. - Skills Check List (pdf)

top


Founders

Richardson Family Foundation Lead Investor
The lead investor in the company is the Richardson family of Greensboro, North Carolina, USA. In the early 1900's Lunsford Richardson developed 'Vicks Vaporub'. Successive generations developed the product into a successful global operating company, Richardson Vicks, which is now part of Proctor & Gamble. In 1981 the family's drug company, Richardson-Merrill was purchased by Dow Chemicals, now part of the conglomerate, Marion Merrill Dow. Up until 1999 when it was acquired by AT&T the family had a significant investment in Vanguard Cellular.

The family operates today through a number of Family Trusts and Investing Companies. The investment in Cambridge Clinical Research is held through Piedmont Associates of Greensboro, North Carolina. Rich Preyer represents the Richardson family on the Board of Cambridge Clinical Research and is a significant shareholder in his own right.

L Richardson Preyer JR Founder
Rich is Managing Director of Piedmont Associates Investment Fund and President of Prospect Partners. He is the former Vice Chairman of the Board, Executive Vice President, Treasurer and a co-founder of Vanguard Cellular Systems, Inc. He is on the Board of Governors of the Center for Creative Leadership and a Director of the Research Triangle Foundation, which owns and develops the Research Triangle Park in North Carolina. He is Vice Chairman of the Board of The School of Social Work at the University of North Carolina and is on the Advisory Board of the Jordan Institute for Families.

Tom Shelly MBA, FCA Managing Director
Prior to the start up of CCR, Tom was Vice President / CFO of Tecan US, North Carolina from 1989-2000. Tecan is a world leading supplier of automation and liquid handling solutions for drug discovery to the pharmaceutical industry, clinical reference laboratories and blood banks. From 1985-1989 he was financial controller of Odenberg US, a food technology company in Sacramento CA. He is a fellow of the Institute of Chartered Accountants of Ireland. He received his MBA from the Kenan Flagler Business School at the University of North Carolina at Chapel Hill and his Bachelor of Commerce degree from University College Dublin, Ireland.

Stephen O'Rahilly MD, FRCP, FRCPI, FMedSci Scientific Advisory Board Director
Stephen qualified at Medicine from University College Dublin and trained in Diabetes and Endocrinology in London, Oxford and Boston, Massachusetts. He is currently the Professor of Metabolic Medicine in the University of Cambridge and Honorary Consultant Physician at Addenbrookes' Hospital, Cambridge. His major clinical interest is in Diabetes and Endocrinology and he has a substantive research programme into molecular and clinical aspects of insulin resistance, fat distribution and human obesity.

Professor O'Rahilly has won many accolades for his work including the prestigious RD Lawrence Lectureship of the British Diabetes Association in 1996 and the Clinical Endocrinology Trust Lectureship of the Society for Endocrinology in 1999.

Further achievements include:
Society of Endocrinology Medal (2000)
Graham Bull Prize for Clinical Research of the Royal College of Physicians (2000).
Novartis Award for Clinical Diabetes Research (2001)
European Journal of Endocrinology Prize (2001)

top